FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2558179968> ?p ?o ?g. }

• W2558179968 abstract "Abstract Background: NPM1 mutated (mut) FLT3-ITD negative acute myeloid leukemia (AML) is a distinct prognostically favorable subtype of AML. Robust data is available demonstrating that monitoring therapy response using NPM1mut-specific real time PCR is an important tool to early detect relapses and provides important information to guide therapy. Since next generation sequencing techniques have become available further gene mutations were detected that accompany NPM1mut in AML. Of these DNMT3Amut were the most frequent and stable ones (Krönke et al., Blood, 2013). Aim: 1) Analyse the stability of DNMT3Amut in paired diagnostic and relapsed samples. 2) Evaluate whether monitoring of DNMT3Amut provides additional information to monitoring of NPM1mut. Patients and Methods: Samples were selected from a cohort of 359 NPM1mut de novo AML cases with an available DNMT3Amut status.First, toevaluate the stability of DNMT3Amut paired diagnostic and relapse samples of 103 patients were analyzed (44 males, 59 females; median age 60 years, range: 26-82 years). Median time to relapse was 11 months (range: 3-68 months). NPM1mut status was assessed at diagnosis with a LightCycler melting curve analysis assay. Non type A mutations were further characterized by Sanger sequencing. Second, all diagnostic and follow-up samples (n=1,813) were quantified by real time PCR specific for the individual NPM1mut. Analysis for DNMT3Amut was performed using either the 454 technology (454 Life Sciences, Branford, CT) or the MiSeq instrument (Illumina, San Diego, CA). Deep DNMT3A sequencing of remission samples was performed using the 454 technology. Results: Out of 103 paired samples 61 (59.2%) carried a DNMT3Amut at diagnosis. 57/61 (93.4%) patients stably retained the mutation at relapse, in 4 (6.6%) the DNMT3Amut was lost. On the other hand 2 of 42 (4.8%) cases with DNMT3A wildtype at diagnosis gained the mutation at relapse. Thus, DNMT3Amut status was shown to be relatively stable (97/103; 94.1%) and thus qualifies as a promising target for follow-up controls. For comparison of DNMT3Amut and NPM1mut status during follow-up 54 patients that were NPM1/DNMT3A double mutated at diagnosis were selected according to the availability of at least one sample in first remission with an NPM1mut level <0.01%. These samples were reanalyzed by deep sequencing for the respective DNMT3A amplicons that had identified mutations at diagnosis. Two of these 54 cases (3.7%) showed morphologic relapse but NPM1mut was negative at relapse (sensitivity of 10-7). In one of these two cases at diagnosis NPM1mut and TET2mut were observed while at relapse IDH1mut and RUNX1mut were present. However, at both time points the DNMT3Amut was identified. The second case lost NPM1mut and CEBPAmut and retained the DNMT3Amut and TET2mut. Thus in these 2 cases the DNMT3Amut can be regarded as the common ancestor. 1 case retained the NPM1mut at relapse but lost the DNMT3Amut. Of note, in 32/54 (59.3%) cases the DNMT3Amut persisted in the remission samples (NPM1mut low level <0.01% or negative) with high DNMT3Amut loads (median: 20%, range: 2-59%) that was only slightly below the load at diagnosis (median: 45%, range: 38-58%). To analyze the clinical importance of these persisting DNMT3Amut survival analysis was performed. Median overall survival for patients with persisting DNMT3Amut (n=32) was 69 vs 96 months in those who lost also the DNMT3Amut in remission (n=22, p=0.053). Median event free survival was 38 vs. 96 months (p=0.031). Thus the DNMT3A mutational status in remission of NPM1mut AML is a further important parameter for prognostication. The mechanisms underlying this observation are obscure. As NPM1mut disappeared in remission and DNMT3A was retained and with the exception of 2 cases all others (n=18) relapsed with an NPM1mut (even the same type as at diagnosis) two mechanisms may be discussed: 1) Persisting DNMT3Amut cells predispose by a yet unknown mechanisms to the development of a secondary NPM1mut or 2) a residual DNMT3Amut/NPM1mut very low level survivor is able to overgrow the DNMT3Amut sole mutated clone in remission and cause relapse. Conclusions: 1) DNMT3Amut persist in remission of NPM1mut AML in the majority of cases (59.2 %). 2) DNMT3Amut analysis in remission of NPM1mut AML is an important parameter for prognostication. 3) Clones with DNMT3Amut as the sole mutation may have a normal phenotype and thus DNMT3Amut may even be regarded as premalignant mutation. Disclosures Schnittger: MLL Munich Leukemia Laboratory: Employment, Equity Ownership. Haferlach:MLL Munich Leukemia Laboratory: Employment, Equity Ownership. Alpermann:MLL Munich Leukemia Laboratory: Employment. Nadarajah:MLL Munich Leukemia Laboratory: Employment. Meggendorfer:MLL Munich Leukemia Laboratory: Employment. Perglerová:MLL2 s.r.o.: Employment. Kern:MLL Munich Leukemia Laboratory: Employment, Equity Ownership. Haferlach:MLL Munich Leukemia Laboratory: Employment, Equity Ownership." @default.
• W2558179968 created "2016-12-08" @default.
• W2558179968 creator A5021480569 @default.
• W2558179968 creator A5023137678 @default.
• W2558179968 creator A5041448618 @default.
• W2558179968 creator A5043414993 @default.
• W2558179968 creator A5048388170 @default.
• W2558179968 creator A5065610259 @default.
• W2558179968 creator A5066015946 @default.
• W2558179968 creator A5075981878 @default.
• W2558179968 date "2014-12-06" @default.
• W2558179968 modified "2023-10-17" @default.
• W2558179968 title "DNMT3A is a Powerful Follow-up Marker in NPM1 mutated AML" @default.
• W2558179968 doi "https://doi.org/10.1182/blood.v124.21.122.122" @default.
• W2558179968 hasPublicationYear "2014" @default.
• W2558179968 type Work @default.
• W2558179968 sameAs 2558179968 @default.
• W2558179968 citedByCount "2" @default.
• W2558179968 countsByYear W25581799682017 @default.
• W2558179968 countsByYear W25581799682018 @default.
• W2558179968 crossrefType "journal-article" @default.
• W2558179968 hasAuthorship W2558179968A5021480569 @default.
• W2558179968 hasAuthorship W2558179968A5023137678 @default.
• W2558179968 hasAuthorship W2558179968A5041448618 @default.
• W2558179968 hasAuthorship W2558179968A5043414993 @default.
• W2558179968 hasAuthorship W2558179968A5048388170 @default.
• W2558179968 hasAuthorship W2558179968A5065610259 @default.
• W2558179968 hasAuthorship W2558179968A5066015946 @default.
• W2558179968 hasAuthorship W2558179968A5075981878 @default.
• W2558179968 hasConcept C104317684 @default.
• W2558179968 hasConcept C126322002 @default.
• W2558179968 hasConcept C143998085 @default.
• W2558179968 hasConcept C2483381 @default.
• W2558179968 hasConcept C30481170 @default.
• W2558179968 hasConcept C51679486 @default.
• W2558179968 hasConcept C53226629 @default.
• W2558179968 hasConcept C54355233 @default.
• W2558179968 hasConcept C71924100 @default.
• W2558179968 hasConcept C72563966 @default.
• W2558179968 hasConcept C76818968 @default.
• W2558179968 hasConcept C86803240 @default.
• W2558179968 hasConceptScore W2558179968C104317684 @default.
• W2558179968 hasConceptScore W2558179968C126322002 @default.
• W2558179968 hasConceptScore W2558179968C143998085 @default.
• W2558179968 hasConceptScore W2558179968C2483381 @default.
• W2558179968 hasConceptScore W2558179968C30481170 @default.
• W2558179968 hasConceptScore W2558179968C51679486 @default.
• W2558179968 hasConceptScore W2558179968C53226629 @default.
• W2558179968 hasConceptScore W2558179968C54355233 @default.
• W2558179968 hasConceptScore W2558179968C71924100 @default.
• W2558179968 hasConceptScore W2558179968C72563966 @default.
• W2558179968 hasConceptScore W2558179968C76818968 @default.
• W2558179968 hasConceptScore W2558179968C86803240 @default.
• W2558179968 hasLocation W25581799681 @default.
• W2558179968 hasOpenAccess W2558179968 @default.
• W2558179968 hasPrimaryLocation W25581799681 @default.
• W2558179968 hasRelatedWork W2028285013 @default.
• W2558179968 hasRelatedWork W2439227321 @default.
• W2558179968 hasRelatedWork W2513420148 @default.
• W2558179968 hasRelatedWork W2529242639 @default.
• W2558179968 hasRelatedWork W2555556933 @default.
• W2558179968 hasRelatedWork W2557452373 @default.
• W2558179968 hasRelatedWork W2558077667 @default.
• W2558179968 hasRelatedWork W2558683794 @default.
• W2558179968 hasRelatedWork W2580249586 @default.
• W2558179968 hasRelatedWork W2765260115 @default.
• W2558179968 hasRelatedWork W2887468627 @default.
• W2558179968 hasRelatedWork W2887710126 @default.
• W2558179968 hasRelatedWork W2913834997 @default.
• W2558179968 hasRelatedWork W2974334961 @default.
• W2558179968 hasRelatedWork W2975497575 @default.
• W2558179968 hasRelatedWork W2979373248 @default.
• W2558179968 hasRelatedWork W2980150194 @default.
• W2558179968 hasRelatedWork W2980454944 @default.
• W2558179968 hasRelatedWork W3180366154 @default.
• W2558179968 hasRelatedWork W3199410141 @default.
• W2558179968 isParatext "false" @default.
• W2558179968 isRetracted "false" @default.
• W2558179968 magId "2558179968" @default.
• W2558179968 workType "article" @default.